Noor Ul Ain Rehman
Sun, May 10, 2026 astatine 6:14 PM CDT 2 min read
CG Oncology, Inc. (NASDAQ:CGON) besides received a standing update from BofA connected April 14. The steadfast lifted the terms people connected the banal to $84 from $72, maintaining a Buy standing connected the shares. It stated that shares person tally up 62% year-to-date with the acceleration of the timeline for PIVOT-006 IR NMIBC data, adding that the BofA is “still bullish astatine existent levels” and sees “more country to run.”
CG Oncology, Inc. (NASDAQ:CGON) is simply a objective biopharmaceutical institution that develops and commercializes bladder-sparing therapeutic patients afflicted with bladder cancer. The institution offers cretostimogene, which is simply a merchandise initially successful objective improvement to dainty patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
While we admit the imaginable of CGON arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

1 hour ago
4





English (CA) ·
English (US) ·
Spanish (MX) ·